Mira Pharmaceuticals Inc (MIRA)
NASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-09-04
$0.76+3.27%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-09-04
Warn: Primary pillar under pressure — Stabilize executive leadership after CFO departure: CFO departed 2026-06-08; no permanent CFO appointed as of 2026-09-04.
MIRA Pharmaceuticals advances its drug pipeline with exclusive rights for MIRA-55 and SKNY-1. The company is progressing with Phase 2a trials for CIPN and expanding clinical programs. Recent M&A deals and license agreements support growth. Despite losses, management is improving execution amid volatile CFO changes.
MIRA remains loss-making with negative EPS of -$0.41 expected in 2026. The CFO departure signals management instability. Clinical trials may fail or delay, and no revenue is forecasted this year. The stock has fallen nearly 18% from its high, reflecting high risk and uncertain recovery.
The market prices in continued losses and no revenue growth for 2026, as reflected by the negative EPS consensus of -$0.41. Our view aligns with this cautious outlook given the company's early clinical stage and management volatility.
Breaks if: EPS remains below -$0.41 or worsens next fiscal year
Breaks if: continued executive turnover or no CFO replacement within 4 quarters
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. MIRA is in the clinical-stage of drug development, focusing on innovative therapies, but it is currently loss-making and faces high risks due to its volatile management and recent legal issues.
The market appears to have priced in a challenging outlook, given the company's ongoing net losses and recent negative events. There is a high level of uncertainty surrounding the company's ability to deliver on its development milestones.
Fundamentals are likely to remain under pressure in the near term, as MIRA continues to report losses while advancing its drug candidates. The company's management is on track with some development priorities, but the mixed status of others introduces uncertainty.
The long-term thesis hinges on the performance of sector bellwethers like LLY, JNJ, and ABBV, which could influence MIRA's momentum. Additionally, the successful advancement of MIRA's drug candidates and resolution of legal issues will be critical.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: failure to initiate Phase 2a trial or loss of exclusive rights within next 4 quarters
MIRA Pharmaceuticals has secured worldwide exclusive rights for its MIRA-55 and SKNY-1 development programs.
Over the next 1 to 3 years, MIRA's prospects depend heavily on external sector conditions and internal development progress. Not investment advice.